Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 9 member D1 (SLC9D1), also known as TMCO3, is a membrane protein belonging to the monovalent cation:proton antiporter 2 (CPA2) family.[4][7][11] It is predicted to function as a potassium/sodium:proton antiporter, coupling the export of monovalent cations (such as K⁺ or Na⁺) to the import of protons (H⁺) across biological membranes.[1][2][4] SLC9D1 contains a transmembrane domain and a coiled-coil domain, is localized to cellular membranes such as the Golgi apparatus, and is expressed in multiple tissues including embryonic structures.[2][1] Mutations in SLC9D1 are associated with rare inherited vision defects such as cornea guttata with anterior polar cataract, as well as immunodeficiency with basal ganglia calcification.[4] No drugs are currently known to target SLC9D1 nor have safety concerns or clinical biomarkers been established for its modulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 9 member D1 (SLC9D1).